Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb study of out-of-specification tisagenlecleucel in label-consistent patients
jRCT1080224903Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 3, open-label, single-arm trial of tisagenlecleucel in B-cell malignancy, sponsored by Novartis. Started Oct 2019; status: recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on jRCT1080224903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224903.